Al-Razi University Journal for Medical Sciences



RUJMS

ISSN No. 2616-6143

Volume (3) Issue (1) June 2019



RUJMS

RUJMS

VOLUME (3) NO (1), JUNE 2019

Editor in Chief	Nationality	Degree
Dr. Nabil Ahmed Al-Rabeei	Yemen	Professor
Editor Manager	Nationality	Degree
Dr. Rashad Al-Namer	Yemen	Associate Professor

Editorial Board Members

No	Editorial board members	Nationality	Degree
1.	Dr. Abdulsalam.M. Dallak	Yemen	Professor
2.	Dr. Abduljalil D. Ghaleb	Yemen	Professor
3.	Dr. Mohammed Abdulhaleem	Yemen	Professor
4.	Dr. Mohammed Aissa	Yemen	Professor
5.	Dr. Ahmed Al-Sobati	Yemen	Professor
6.	Dr. Abdulhameed Al-Thifani	Yemen	Associate Professor
7.	Dr. Nouradden Al-Jaber	Yemen	Associate Professor
8.	Dr. Shatha Hassan Yassin	Yemen	Associate Professor
9.	Dr. Sadeq Hassan Al-Sheraji	Yemen	Associate Professor
10.	Dr. Ahmed Ali Abdulateef	Yemen	Associate Professor
11.	Dr. Abdulmajid Alssaifi	Yemen	Associate Professor

Advisory Board

No	Advisory Board	Nationality	Degree
1.	Dr. El Houcin Boidida	Morocco	Associate Professor
2.	Dr. Yahia Cherrah	Yahia Cherrah Morocco Associate Pro	
3.	Dr. Abdulaziz Benjouad	Morocco	Associate Professor
4.	Dr. Abdellah Akil	USA	Associate Professor
5.	Dr. Katim Alaoui	Morocco	Associate Professor
6.	Dr. Arvinder Bahala	India	Associate Professor
7.	Dr. David Tasala	USA	Associate Professor

RUJMS

Copyright of articles published in the RUJMS belong to the University of Al-Razi unless the work is subject to copyright.

Address: Al-Razi University - College of Medical Sciences

Telefax: +9671406760 P.O. Box:1152 Sana'a - Yemen

Website: http://alraziuni.edu.ye/rujms/

Designed by Eng. Osama Al-Moaina

Ossamah245@yahoo.com

TABLE OF CONTENTS

OI	RIGINAL ARTICLES	PAGE					
1.	Tumors of the Larynx in Yemen: Prevalence and	1-7					
	Treatment						
	Ali Obaid Muthanna						
2.	Effect of Training Program on Nurses ' Knowledge Toward	8-15					
	Care of Patients With Myocardial Infarction in Al-						
	Thowrah Hospital, Al-Hodeida City, Yemen						
	Sadek Abdu Alwsaby, Nabil Ahmed Al-Rabeei, Abdelaziz Baalawi						
	and Ali Floos						
3.	Mothers' Knowledge Toward Malnutrition of Children	16-22					
	Under 5 Years Old in Al-Sabeen Hospital, Sana'a City-						
	Yemen						
	Sadek Abdu Alwsaby, Nabil Ahmed Al-Rabeei, Abdelaziz Ahmed						
	Baalawi, and Ali Ahmed Floos						
4.	Assessment of Compliance of Written Pharmaceutical	23-27					
	Advertisements in Sana'a-Yemen to Criteria of World						
	Health Organization						
	Anes A. M. Thabit, Saleh Yagob, Abdulaziz Mofid, Abdullah						
	Alomaesi, Abdullah Helal, Akram Qahtan, Akram Almasanea, Amar						
	Alsoudi, Bassam Azzam, Mohammed Seraj, Saddam Hashem, Zkee Almacheheri.						
5	Medical Treatment for Orbital Complications Secondary to	28-34					
٥.	Rhinosinusitis	20-34					
	Ali Obaid Muthanna						
6	Comparative Study of in vitro Quality Specifications of	35-40					
U.		33 -4 0					
	Yemeni Brand of Glimepiride Tablets Versus Foreign						
	Brands Marketed in Yemen						
	Alaa Abdulkarim Almaqtari and Anes A. M. Thabit						



Al-Razi University Journal of

Medical Sciences



Assessment of Compliance of Written Pharmaceutical Advertisements in Sana'a-Yemen to Criteria of World Health Organization

Anes A. M. Thabit^{1*}, Saleh Yagob¹, Abdulaziz Mofid¹, Abdullah Alomaesi¹, Abdullah Helal¹, Akram Qahtan¹, Akram Almasanea¹, Amar Alsoudi¹, Bassam Azzam¹, Mohammed Seraj¹, Saddam Hashem¹, Zkee Almacheheri¹.

Abstract

Background: The influence of pharmaceutical marketing on prescription behavior of physicians can be great especially in developing countries. Aim: To assess the compliance of written pharmaceutical advertisements in Sana'a -Yemen to the criteria adopted by the world health organization (WHO) for drug promotion. Methods: A sample of 147 written pharmaceutical advertisements (included both brochures and posters) were randomly collected from hospitals, private clinics and community pharmacies in Sana'a- the capital of Yemen. The advertisements were initially grouped according to the medical indication of the advertised drug into 11 therapeutic categories among which anti-infective showed the highest percentage (22.4%). Thereafter, the advertisements were again grouped according to the origin of the pharmaceutical manufacturer into 5 categories, American (9.5%), European (23.8%), Arabian (27.2%), Asian (19%) and Yemeni (20.4%). Subsequently, a cross sectional analysis was applied to every advertisement to assess the presence of 20 WHO criteria of drug promotion and the category as well as overall compliances were reversely determined as error % from the corresponding average distributions of those criteria in the analyzed advertisements. Results: The error % in compliance among the 11 therapeutic categories ranged from -40% in gastrointestinal (GIT) medications to -85% in cardiovascular system (CVS) medications. With respect to categories of manufacturer origin, the error % ranged from -63.6 % in European advertisements to -73 % in Yemeni ones. The overall error % in compliance among all analyzed advertisements (-69.8 %), which was higher than those reported in Emirates (-68.5%) and Saudi Arabia (-44.5%). Conclusion: The error % in compliances of written pharmaceutical advertisements in Sana'a- Yemen to WHO criteria for drug promotion is high. Therefore, establishments and imposing of regulations for drug promotion in Yemen is extremely required.

Keywords: Pharmaceutical advertisements; Yemen; WHO; Criteria.

Introduction

In marketing, promotion is advertising a product or brand, generating sales and creating brand loyalty¹. Advertising is the audio or visual form of promotion that employs an openly sponsored, non-personal message to promote or sell a product, service or

idea^{2,3}. There have been different ways to promote a product using different media⁴. Among the most popular written advertisements are brochures and posters. The former are informative paper documents that can

¹Department of pharmacy, Faculty of Medical Sciences, Al-Razi University, Yemen

^{*}Corresponding author: email: aneesalabsi1973@gmail.com

be folded into a template⁵. The latter are pieces of printed papers designed to be attached to a wall or vertical surfaces ⁶. Drug promotion is of great importance in pharmaceutical industry. In 2012, the pharmaceutical industry in USA spent more than \$27 billion on drug promotion⁷. Besides, in the same year, it was estimated that there were 72000 pharmaceutical representatives employed in USA⁸. influence of pharmaceutical The marketing on prescription behavior of physicians can be great especially in developing countries as observed in certain studies⁹.

In Yemen, 2012, a study showed that pharmaceutical companies use nonethical promotion methods to ensure sales¹⁰. their The world health organization (WHO), in the second report of the WHO expert committee, has adopted ethical criteria for written pharmaceutical advertisements. provided a list of 20 information that be contained advertisement 11.

Aim of the study

To assess the compliance of written pharmaceutical advertisements in Sana`a-Yemen to WHO criteria for drug promotion

Subject and Methods

sample of 147 written pharmaceutical advertisements were collected randomly from hospitals, private clinics and community pharmacies in Sana'a-Yemen within the period from December 8th 2016 to February 10th 2017. The sample size was selected to be within the range of 66-185 advertisements used elsewhere in near Arabian countries 12,13.

The sample included 140 (95%) brochures and 7 (5%) posters. Cosmetic and baby products were excluded in this study. The sample of advertisements was initially classified

according to the medical indication of the advertised drug and then according to the origin of the manufacturer. Then, a cross sectional method was applied on every advertisements to analyze the presence of 20 information adopted by WHO criteria for drug promotion.

The frequency (fi) of every information existence on analyzed advertisements within each category was counted. The (%) distribution as of information in the category was and the average of information distribution % within all analyzed sample were Moreover, the category calculated. average distribution % as well as the overall distribution of all information in the analyzed sample were also calculated.

The compliance of each category and the overall compliance were reversely calculated from corresponding distributions as error % in compliance. Appropriate statistical methods were also used to compare the distribution results with Chi-square test: indicating significant value<0.05 difference and relative intergroup standard deviation (RSD %) of>15 % indicating significant intragroup difference.

Results

As shown in table 1, 11 therapeutic categories were observed in the analyzed sample. The three top ones among those categories were antiinfective (22.4%), others (19.7 %) and endocrine drugs (10.9%). The number and % of the 5 manufacturer origin categories in the sample American (14; 9.5%), European (35; 23.8 %), Arabian (40; 27.2 %), Asian (28; 19 %) and Yemeni (30; 20.4 %). Concerning the average distribution % information in all analyzed advertisements (Table 2), it was found that the information with highest distribution were brand name (100%), name of drug (77.6%), approved therapeutic use (73.5%), content of form drug/dosage (69%), dosage regimen (57.6%) and name manufacturer (55%). On the other hand, the information with the lowest distribution were name of other ingredients that may cause problem (0%), condition associated risk factor condition (1%),prevalence (1.1%), name of distributor (5.4%), interactions major (9.6%),contraindications (11.5%), mechanism of action (13.4%) side effects and adverse reactions (14.2%)precautions/warnings (15.8%).

The average distribution of all information within each manufacturer origin category ranged from 27 % in Yemeni advertisements to 36.5% in

European advertisements. The differences in distribution of the 20 information within each origin category were significant (RSD>15%). However, there was no significant difference in distribution of information among the 5 origin categories (P>0.05).

The compliances to WHO criteria were poor in each origin category and the error % in compliance ranged from -73 % in Yemeni advertisements to -63.6% in European advertisements. The overall average distribution of all information in all analyzed advertisements was compliance 30.2 % yielding an overall poor compliance with error % in compliance of -69.8%.

Table 1: Analysis written pharmaceutical advertisements

No	Therapeutic category	Manufacturer origin categories					Total	%
		American	European	Arabian	Asian	Yemeni		
1	CNS medications	2	7	4	2	0	15	10.2
2	CVS medications	2	3	2	0	0	7	4.8
3	Respiratory medications	1	1	1	1	0	4	2.7
4	Renourinary medications	0	2	1	0	0	3	2.0
5	GIT medications	1	4	2	1	3	11	7.5
6	Anti-infective	2	2	12	7	10	33	22.4
7	Endocrine drugs	4	4	4	2	2	16	10.9
8	Analgesics	1	2	2	2	1	8	5.4
9	Vaginal preparations	0	1	3	2	0	6	4.1
10	Nutrients & blood tonics	1	4	3	3	4	15	10.2
11	Others	0	5	6	8	10	29	19.7
	Total (%)	14 (9.5)	35(23.8)	40(27.2)	28(19)	30(20.4)	147(100)	100

Table 2: Distribution % of WHO required information on manufacturer origin

categories of written pharmaceutical advertisements

No.	Information	American	European	Arabian	Asian	Yemen	Di
		(n=14)	(n=35)	(n=40)	(n=28)	(n=30)	
1	Name of condition treated	14.3	68.6	25	28.6	33.3	34.0
2	Condition associated risk factor	0	0	5	0	0	1.0
3	Condition prevalence rate	0	2.9	2.5	0	0	1.1
4	Generic name of drug(s)	35.7	88.6	95	82.1	86.7	77.6
5	Brand name	100	100	100	100	100	100.0
6	Content drug/ dosage form	92.9	68.6	60	53.6	70	69.0
7	Name of other ingredients known to cause problems	0	0	0	0	0	0.0
8	Drug mechanism of action	21.4	8.6	20	3.6	13.3	13.4
9	Approved therapeutic use	85.7	68.6	90	50	73.3	73.5
10	Dosage form regimen	71.4	60	50	50	56.7	57.6
11	Expected onset of action	14.3	20	12.5	14.3	3.3	12.9
12	Success estimate of treatment	0	34.4	10	28.6	6.7	15.9
13	Side effects and adverse reactions	0	22.9	17.5	7.2	23.3	14.2
14	Precautions/ warnings	0	20	17.5	25	16.7	15.8
15	Contraindications	0	20	17.5	0	20	11.5
16	Major interactions	0	22.9	15	0	10	9.6
17	Comparison with competitors	7.1	25.7	15	32.1	20	20.0
18	Name/address of manufacturer	85.7	74.3	65	46.4	3.3	54.9
19	Name/address of distributor	0	11.4	5	10.7	0	5.4
20	References to scientific literatures	42.9	11.4	17.5	10.7	3.3	17.2
Dc		28.6	36.4	32.0	27.1	27.0	30.2
Error % in compliance		- 71.4	-63.6	- 68	-72.9	- 73	- 69.8
RSD %		129.8 *	86.7 *	101.3 *	106.3	118.7 *	100.1
	Chi-square P value			0.883□			

Di: average distribution % of each WHO information among all advertisements; Dc %: average distribution % of all information within the category; : Chi-square test: insignificant intergroup difference; RSD: relative standard deviation; *: significant intragroup difference (RSD > 15%)

Discussion

With few exceptions, the distributions of most WHO required information were low as shown in this study. The study showed lowest distribution of important information such as name of other ingredients that may cause problems, condition associated risk factor, condition prevalence rate name distributor. major interactions (9.6%), contraindications, mechanism of action, side effects and adverse reactions and precautions/warnings. Pharmaceutical companies tend to hide such information in fear of sale reduction if such information become known to physicians and patients. In comparison to a study conducted by Sina Abdul Mohsen et al. 12, in Saudi Arabia, 2013, the distributions of the relevant information were higher than

those observed in the present study. In addition, the overall compliance was greater than this study, with error % in compliance of -44.5 %. In another study carried out in 2008 Emirates¹³, the distributions of WHO information were also higher than those obtained in this study. However, the overall compliance in that study was as poor as that found in this study with close error % in compliance of -68.5 %.

Conclusion

Compliance of written pharmaceutical advertisements in Sana'a-Yemen is poor.

Recommendations

The study recommends that the authority in Yemen represented by the Supreme board of drugs and medical appliances (SBDMA) to establish and impose regulations related to drug promotion for the favor of saving Yemeni health professionals and patients from non-ethical promotion of drug products by some pharmaceutical companies.

References

- McCarthy, Jerome E.. Basic marketing. A meaningful approach, 1964; Homewood Inc.
- 2. William J. Santon. Fundamentals of marketing. 2010; McGrraw-Hil, USA.
- 3. Murray E, Lo B, Pollack L. Direct to costumers advertising. J Am Broad Fam Pract, 2004: 1 (17): 6-18
- 4. Donley T, Studlar. Comparative politics in the United State and Canada; 2002; McGraw-Hill, USA.
- 5. Raja Gobal. Marketing dynamics theory and practice; 2007 New Age international, India.
- 6. Muzaffer Uysal and Daniel Fesnmaier. Communication and channel systems in Tourism marketing, 2012, Routledge, Sweden
- Gosling Peter. Scientific guide to poster presentation. 2006; Academic press, USA
- 8. Cegedim strategic data, US pharmaceutical company promotion

- 2012, available at http://www. Skainfo.com/health_care_market_reports /2012_promotional_spending.pdf
- 9. Biswas K and Fredousy UK. Influence of pharmaceutical marketing on prescription behavior of physicians: a cross-sectional study in Bangladesh; 2016: 5(2):1-4
- 10. Adnan Yahya Al-Hamadi, Mohamed Azmi Ahmed Hassali, Mohamed Izham Mohamed Ibrahim. Impact of pharmaceutical promotion on healthcare professional's practice and behavior. Views from medicine dispensers and medical representatives in Yemen. 2013: 12(4): 240-246
- 11. World health organization ethical criteria for drug promotion available at http://www.who.int/medicinedocs/edm web/pdf/wozip08e/whozip08e.pdf
- 12. Sina Abdul Mohsen Al-Aqeel, Jawza Fahd Alsabhan and Noha Yahia Sultan. Analysis of written advertising materials distributed through community pharmacies in Riyadh, Saudi Arabia Pharmacy Practice; 2013: 11(3)-1138-1143
- 13. Suleiman Ibrahim Sharif, Abdulelmula R. Abdulkarim. Analysis of written pharmaceutical advertisements in Dubai and Sharjah. Saudi Pharmaceutical journal; 2008: 16(3); 252-257



Al-Razi University Journal for Medical Sciences

صنعاء ـ شارع الرباط ـ خلف البنك اليمني للإنشاء والتعمير

فاكس: 406760

تلفون: 216923

www.alraziuni.edu.ye info.alraziuni.edu.ye